Evidence map›Paper›PMID 35261957›Full record

ArticleAnnals of gastroenterological surgery2022

Prognostic Value of Carbohydrate Antigen 19-9 and the Surgical Margin in Extrahepatic Cholangiocarcinoma.

Ryusei Yamamoto, Teiichi Sugiura, Ryo Ashida, Katsuhisa Ohgi, Mihoko Yamada, Shimpei Otsuka, Katsuhiko Uesaka

Open access · goldAbstract read
In one paragraph

Article in Annals of gastroenterological surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Surgical Treatment of Distal Cholangiocarcinoma.Current oncology (Toronto, Ont.) · 2022
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ryusei YamamotoDivision of Hepato-Biliary-Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan.
Teiichi SugiuraDivision of Hepato-Biliary-Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan.ORCID https://orcid.org/0000-0001-7163-4084
Ryo AshidaDivision of Hepato-Biliary-Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan.
Katsuhisa OhgiDivision of Hepato-Biliary-Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan.
Mihoko YamadaDivision of Hepato-Biliary-Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan.
Shimpei OtsukaDivision of Hepato-Biliary-Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan.
Katsuhiko UesakaDivision of Hepato-Biliary-Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan.
Shizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: The prognostic value of the perioperative carbohydrate antigen 19-9 (CA19-9) value and the prognostic relationship between the CA19-9 value and the surgical margin in extrahepatic cholangiocarcinoma (EHCC) have not been fully discussed. Methods: A total of 390 patients who underwent curative resection for EHCC between 2002 and 2018 were retrospectively analyzed. According to the perioperative CA19-9 value, patients were divided into three groups: preoperative normal (Normal, n = 178), preoperative high and postoperative normal (Normalization, n = 155), and preoperative high and postoperative high (Nonnormalization, n = 57). Survival was analyzed according to the perioperative CA19-9 value and surgical margin. Results: The optimal cutoff value of CA19-9 was 37 U/mL. Overall survival (OS) was significantly stratified according to the perioperative CA19-9 value. The 5-y OS rates in the Normal, Normalization, and Nonnormalization groups were 53%, 38%, and 23%, respectively ( Conclusion: The perioperative CA19-9 value was related to the prognosis of resectable EHCC. A preoperative CA19-9 value of ≥37 U/mL reflected systemic disease. R0 resection did not affect the survival in this patient group.

Indexed as

carbohydrate antigen 19‐9extrahepatic cholangiocarcinomasurgical margin

Identifiers

PMID35261957
PMCPMC8889865
OpenAlexW3212961834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.